Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 4/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30968590 | 1.00 | CARM1 (0.48) | CARM1PRMT6SLC1A2LMNAALDH1A1 | |
| SCHEMBL30968593 | 1.00 | CARM1 (0.48) | CARM1PRMT6SLC1A2LMNAALDH1A1 | |
| SCHEMBL25259336 | 0.84 | SLC1A2 (0.60) | CARM1PRMT6SLC1A2ALDH1A1RIPK1 | |
| SCHEMBL25242066 | 0.84 | SLC1A2 (0.60) | CARM1PRMT6SLC1A2ALDH1A1RIPK1 | |
| SCHEMBL25209028 | 0.84 | SLC1A2 (0.60) | CARM1PRMT6SLC1A2ALDH1A1RIPK1 | |
| SCHEMBL30968624 | 0.78 | CTRB1 (0.51) | CARM1PRMT6CTRB1HDAC1HDAC2 | |
| SCHEMBL30968655 | 0.78 | CTRB1 (0.51) | CARM1PRMT6CTRB1HDAC1HDAC2 | |
| SCHEMBL30968596 | 0.78 | CTRB1 (0.51) | CARM1PRMT6CTRB1HDAC1HDAC2 | |
| SCHEMBL31196650 | 0.76 | SLC1A2 (0.65) | SLC1A2LMNAALDH1A1 | |
| SCHEMBL31196680 | 0.76 | ALDH1A1 (0.41) | SLC1A2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042848-A1 | DEUTERATED FUNCTIONALIZED DERIVATIVES OF alpha-ALANINE, IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISEASES | UNIWERSYTET JAGIELLONSKI (PL) | 2025-02-06 | — | — | US | disclosed |
| EP-4436954-A1 | DEUTERATED FUNCTIONALIZED DERIVATIVES OF ?-ALANINE, IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISEASES | UNIWERSYTET JAGIELLONSKI (PL) | 2024-10-02 | — | — | EP | disclosed |
| CN-118302410-A | Deuterated functionalized derivatives of alpha-alanine, in particular for the treatment of neurological diseases | 雅盖隆大学 | 2024-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042848-A1 | DEUTERATED FUNCTIONALIZED DERIVATIVES OF alpha-ALANINE, IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISEASES | AADAT, AAAS, ABAT | CARM1 2988/4885PRMT6 882/4885SLC1A2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.